News & Updates

Novel drug helps optimize HFrEF therapy
Novel drug helps optimize HFrEF therapy
27 Apr 2022 byAudrey Abella

In individuals receiving renin-angiotensin-aldosterone system inhibitor (RAASi) therapy for heart failure with reduced ejection fraction (HFrEF), the novel potassium binder patiromer effectively reduced serum potassium levels, the DIAMOND trial suggests, thus optimizing a guideline-directed RAASi therapy for these patients.

Novel drug helps optimize HFrEF therapy
27 Apr 2022
Intensive urate lowering of little benefit to patients with erosive gout
Intensive urate lowering of little benefit to patients with erosive gout
27 Apr 2022
Intensified systemic therapy with ADT improves outcomes in high-risk prostate cancer
Intensified systemic therapy with ADT improves outcomes in high-risk prostate cancer
27 Apr 2022

In patients with high-risk or unfavourable nonmetastatic prostate cancer (nmPC) receiving local definite therapy, the intensification of systemic therapy using chemotherapy or an androgen receptor signaling inhibitor (ARSI), in combination with androgen deprivation therapy (ADT), leads to better oncologic survival measures, reports a recent meta-analysis.

Intensified systemic therapy with ADT improves outcomes in high-risk prostate cancer
27 Apr 2022